Pancreatic Cancer Research

ResearcherOkayama UniversityActive in the last 2 years

Shinji Kuroda

Matched on ORCID iD 0000-0002-4484-1253; OpenAlex author ID A5020188029. Sources: OpenAlex.

Their work

Papers
16 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 4 papers · 2026: 3 papers

Papers 16

  1. Turning pancreatic cancer from cold to hot: the promise of a p53-expressing oncolytic adenovirus (OBP-702). Co-author DOI 10.1007/s10147-026-02991-7↗
  2. Mitochondrial inhibition enhances the sensitivity of pancreatic ductal adenocarcinoma cells to oncolytic adenovirus. Co-author DOI 10.1016/j.omton.2026.201180↗
  3. p53-armed oncolytic adenovirus induces apoptosis in pancreatic cancer-associated stellate cells via macropinocytosis. Co-author DOI 10.1038/s41417-025-00989-3↗
  4. Cancer-associated fibroblasts promote pro-tumor functions of neutrophils in pancreatic cancer via IL-8: potential suppression by pirfenidone. Co-author DOI 10.1007/s00262-025-03946-z↗
  5. Gemcitabine-induced neutrophil extracellular traps via interleukin-8-CXCR1/2 pathway promote chemoresistance in pancreatic cancer. Co-author DOI 10.1038/s41416-025-03192-1↗
  6. [Development of Oncolytic Virus Immunotherapy to Improve the Immunosuppressive Microenvironment in Pancreatic Cancer]. Co-author PMID 40420372↗
  7. [Development of Immunotherapy to Target Autophagy‒Dependent Immune Evasion in Pancreatic Cancer]. Co-author PMID 41139971↗
  8. Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus. First author DOI 10.1038/s41416-024-02583-0↗
  9. Author Correction: Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus. First author DOI 10.1038/s41416-024-02850-0↗
  10. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. Co-author DOI 10.1007/s00262-022-03334-x↗
  11. [Therapeutic Effect of Oncolytic Adenovirus on Pancreatic Cancer Stroma]. Co-author PMID 38035844↗
  12. Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer. Co-author DOI 10.1016/j.omto.2022.09.003↗
  13. [Telomerase-Specific Oncolytic Adenovirus Expressing p53 Gene Stimulating CD8+ Memory T Cells in Pancreatic Cancer]. First author PMID 36281608↗
  14. Targeting neutrophil extracellular traps with thrombomodulin prevents pancreatic cancer metastasis. Co-author DOI 10.1016/j.canlet.2020.10.015↗
  15. Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer. Co-author DOI 10.1016/j.omto.2020.03.016↗
  16. The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer. Co-author DOI 10.1186/s13046-018-0981-2↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toshiyoshi Fujiwara · 16 shared papers, 2018–2026 · strength 2.96
  2. Ryuichi Yoshida · 9 shared papers, 2018–2026 · strength 1.40
  3. Yuzo Umeda · 6 shared papers, 2020–2026 · strength 0.99
  4. Masashi Hashimoto · 5 shared papers, 2022–2026 · strength 0.94
  5. Yasuo Nagai · 4 shared papers, 2023–2026 · strength 0.88
  6. Yoshinori Kajiwara · 4 shared papers, 2022–2026 · strength 0.78
  7. Ryohei Shoji · 3 shared papers, 2020–2026 · strength 0.58
  8. Kazuya Yasui · 3 shared papers, 2024–2025 · strength 0.54
  9. Takeyoshi Nishiyama · 2 shared papers, 2026 · strength 0.48
  10. Kanto Suemori · 2 shared papers, 2025 · strength 0.45
  11. Tomohiko Yagi · 2 shared papers, 2025 · strength 0.42
  12. Shohei Nogi · 2 shared papers, 2025 · strength 0.42
  13. Kosei Takagi · 2 shared papers, 2025 · strength 0.42
  14. Hiroyuki Araki · 2 shared papers, 2020–2022 · strength 0.23
  15. Hiroyoshi Y. Tanaka · 1 shared paper, 2026 · strength 0.23
  16. Mitsunobu R. Kano · 1 shared paper, 2026 · strength 0.23
  17. Atsushi Masamune · 1 shared paper, 2026 · strength 0.23
  18. Yousuke Takahashi · 1 shared paper, 2025 · strength 0.23
  19. Hiroki Kajioka · 1 shared paper, 2021 · strength 0.12
  20. Takeshi Koujima · 1 shared paper, 2020 · strength 0.10
  21. Kazuya Kuwada · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.